{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 75. ASCO & EHA 2026 Myeloid Roundup with Dr. Joshua Zeidner","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/ddf2429c\"></iframe>","width":"100%","height":180,"duration":3413,"description":"Topics Covered\n\n1. KOMET-007 and SNDX-5613-0708: Menin Inhibitors with Intensive Chemotherapy\nKOMET-007: Phase 1a/b study adding ziftomenib 600 mg once daily, starting on day 8, to 7+3 induction and continuing it through consolidation, in 99 patients with newly diagnosed NPM1-mutated (n=49; median age 60) or KMT2A-rearranged (n=50; median age 43) AML. Presented by Amer Zeidan at EHA 2026 (Abstract S130; NCT05735184).\nSNDX-5613-0708: Phase 1 dose-escalation study adding revumenib to cytarabine plus daunorubicin or idarubicin for up to two induction cycles in induction-eligible adults aged 18–75 (ECOG 0–2) with newly diagnosed KMT2A-rearranged, NPM1-mutated, or NUP98-rearranged AML. Two dose levels were tested: DL1 (110/220 mg) and DL2 (160/270 mg, the approved monotherapy dose). 31 patients were treated (13 at DL1, 18 at DL2) as of October 2025. Presented by Ibrahim Aldoss at EHA 2026 (Abstract PF489; NCT06226571).\n\nKey results (KOMET-007 median follow-up 17.6 months NPM1-m, 11.0 months KMT2A-r):\n\n•     KOMET-007 CRc 96% (47/49) in NPM1-m and 90% (45/50) in KMT2A-r, 93% (92/99) overall; MRD negativity among CRs ~85%\n•     KOMET-007 12-month OS 94% (NPM1-m) vs. 71% (KMT2A-r); median OS not reached in either cohort; 60-day mortality 2% and 4%\n•     KOMET-007 safety: grade 3 differentiation syndrome 4%, no grade 4; no ziftomenib-related QTc prolongation\n•     Revumenib + intensive chemotherapy, response-evaluable patients: DL1 (n=12) ORR/CRc 100%, CR 92%; DL2 (n=14) ORR 93%, CRc 86%, CR 79%; MRD-negative CR 100% (DL1) and 70% (DL2); responses similar across dose levels\n•     Revumenib safety: no differentiation syndrome; one grade 3 QTcF prolongation DLT; any-grade QTcF prolongation ~15% at DL1\n\nDiscussion points: Both studies start the menin inhibitor after the cytotoxic days of induction, when there is less leukemia left to differentiate. Dr. Zeidner credits that timing and the chemotherapy itself for differentiation syndrome rates of 3–4%, compared with roughly...","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}